Papers Sought for SBR Special Issue
Toshimitsu Hamasaki, PStat®, Editor of Statistics in Biopharmaceutical Research
The entire globe has been facing the dangerous COVID-19 pandemic caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Our biopharmaceutical community has committed to developing solutions to help diagnose and treat those with COVID-19 and conduct clinical trials to evaluate effective strategies that can lead to developing diagnostic tests that detect SARS-CoV-2 precisely and efficiently, identifying treatments for critical care management of patients, and discovering highly anticipated vaccines.
Statistics in Biopharmaceutical Research (SBR), an official journal of the American Statistical Association, has been publishing papers on clinical trial disruptions and statistical issues due to the COVID-19 pandemic. Now, SBR is calling for papers focusing on clinical trials for COVID-19 treatments, vaccines, medical devices, and diagnostics. SBR will accept manuscripts in the form of original research, short communication, perspective, commentary, or a letter to the editor that present recent statistical issues, challenges, or methodology developments in our knowledge of COVID-19.
COVID-19 Trials Special Editorial Team
Frank Bretz, Novartis
Freda Cooner (Co-Guest Editor), Amgen
Toshimitsu Hamasaki, The George Washington University
Gene Pennello, US Food and Drug Administration
Martin Posch, Medical University of Vienna
Manuscripts should be submitted online. Once you log in to the system, go to the “Start New Submission” page. Select “COVID-19 Trials” in Step 1: Type, Title, & Abstract.
Manuscripts can be submitted until October 15. All papers will be peer-reviewed according to the reviewing principles of SBR. Accepted papers will be published continuously on the journal’s website as soon as they are accepted and listed together in the special issue.
A guide for authors and other relevant information for submission of manuscripts is available on the “Instructions for Authors” page and “ASA Style Guide” page.
If you have any questions or require clarification, email Toshimitsu Hamasaki or Freda Cooner .